ASSESSMENT OF RISK FACTORS FOR THROMBOSIS IN ICU PATIENTS WITH COVID-19
Introduction: According to scientific studies, a high incidence of thrombotic events is known in hospitalized patients with COVID-19. Less than 50% of pulmonary embolisms (PE) are associated with signs of deep vein thrombosis (DVT) of the lower extremities.
Objective: To identify significant risk factors for thrombosis thrombosis (DVT) in intensive care patients with COVID-19.
Materials and methods: We conducted a prospective cross-sectional study that included 465 adult patients with laboratory-confirmed COVID-19 admitted to the intensive care unit. All patients underwent computer tomography of the chest organs, ultrasound angioscanning of lower extremities, body mass index was calculated, the presence of comorbotity diseases and indicators of volumetric blood saturation were considered. The level of D-dimer in blood plasma, coagulation parameters (fibrinogen, factor VIII) were taken from laboratory parameters in calculations.
For subgroups with 5 or fewer people, the chi-square test and Fisher's exact test were used. For quantitative variables, analysis of variance (ANOVA) and the Pearson and Spearman correlation coefficient were used. For multiple variables, ordered logistic regression models were built, with likelihood ratio tests performed to compare the models.
Results: A total of 465 patients were included in the study. Comorbidities were present in 435 of 465 patients (93.55%) had at least one comorbidity. The most common was arterial hypertension - 370 (79.57%), followed by chronic heart failure - 196 (42.15%), obesity - 161 (34.62%), diabetes mellitus - 144 (30.97%), chronic renal failure (CRF) -58 (12.47%) and oncological diseases -25 (5.38%). The average body mass index was 29.7 kg/m2. In patients with DVT and venostasis, the body mass index (BMI) was more than 30 kg/m2 than without DVT (32.57±10.92 kg/m2, and 30.24±6.85 kg/m2, versus 29.22±6.46 kg/m2, respectively). Ultrasound angioscanning (USAS) confirmed deep vein thrombosis in 60 patients (13.8%) and was associated with older age (71.12±13.98 versus 67.20±11.16, p<0.006), venous stasis was detected in 56 patients (12%) no DVT was detected in the rest of the studied patients. In the majority of cases, DVT was detected in the tibial segment -26 (43.33%), in 18 (30%) patients it was diagnosed in the popliteal veins and in 14 (23.33%) cases in the femoral segment. Diabetes mellitus (p=0.041), obesity (p=0.01) and CRF (p=0.028) were also significant risk factors for DVT.
Conclusions: Significant risk factors for deep vein thrombosis in intensive care patients with COVID-19 are high levels of D-dimer (>=2.33 μg/ml) and comorbidities such as obesity, chronic kidney failure, and diabetes mellitus.
Raushan I. Rakhimzhanova1, https://orcid.org/0000-0001-9564-1609
Zhanar J. Kozhakhmetova1-2, https://orcid.org/0000-0002-7255-0955
Agilan Ozerman1,3, https://orcid.org/0000-0002-0817-9282
1 NJSC "Astana Medical University", Department of Radiology named after Academician Zh.Kh. Khamzabaev, Astana city, Republic of Kazakhstan;
2 City Multidisciplinary Hospital No. 2, Department of Ultrasound Diagnostics and Functional Diagnostics, Astana city, Republic of Kazakhstan;
3 Cooperative Fond University Medical Center, Department Diagnostic Radiology,
Astana city, Republic of Kazakhstan.
1. Ackermann M., Verleden S.E., Kuehnel M., Haverich A., Welte T., Laenger F. et.al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 // N Engl J Med. 2020. 383(2):120–8. Epub 2020/05/22. PMID: 32437596; PubMed Central PMCID: PMC7412750. https://doi.org/10.1056/NEJMoa2015432. (Дата обращения на сайт: 13.10.2022)
2. Baccellieri D., Apruzzi L., Ardita V. et al. The “venous perspective” in Lombardia (Italy) during the first weeks of the COVID-19 epidemic // Phlebology 2020. 35: 295–296.
3. Brogan M., Ross M.J. The Impact of Chronic Kidney Disease on Outcomes of Patients with COVID-19 Admitted to the Intensive Care Unit // Nephron. 2022. 146:67-71. doi: 10.1159/000519530
4. Cattaneo M., Bertinato E.M., Birocchi S. et al. Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified? // Thromb Haemost. Epub ahead of print, 2020. DOI: 10.1055/s-0040-1797.
5. Chang M.C., Park D. How Should Rehabilitative Departments of Hospitals Prepare for Coronavirus Disease 2019. American journal of physical medicine & rehabilitation, 2020. 99(6), 475–476. https://doi.org/10.1097/PHM.0000000000001428
6. Chang M.C., Seo W.S., Park D., Hur J. Analysis of SARS-CoV-2 Screening Clinic (Including Drive-Through System) Data at a Single University Hospital in South Korea from 27 January 2020 to 31 March 2020 during the COVID-19 Outbreak. Healthcare (Basel, Switzerland), 2020. 8(2), 145. https://doi.org/10.3390/healthcare8020145
7. Chen J., Wang X., Zhang S. et al. Findings of acute pulmonary embolism in COVID-19 patients // SSRN Electron J. Epub ahead of print 2020. DOI: 10.2139/ssrn.3548771.
8. Connor-Schuler R., Daniels L., Coleman C., Harris D., Herbst N., Fiza B. Presence of Spontaneous Echo Contrast on Point-of-Care Vascular Ultrasound and the Development of Major Clotting Events in Coronavirus Disease 2019 Patients. Critical care explorations, 2021. 3(1), e0320. https://doi.org/10.1097/CCE.0000000000000320 (Дата обращения на сайт: 14.08.2022)
9. Cui S., Chen S., Li X. et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia // J Thromb Haemost, 2020. 18: 1421–1424.
10. Fadini G.P., Morieri M.L., Longato E., Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. Journal of endocrinological investigation, 2020. 43(6), 867–869. https://doi.org/10.1007/s40618-020-01236-2
11. Gentile S., Strollo F., Ceriello A. COVID-19 Infection in italian people with diabetes: Lessons learned for our future (an experience to be used) // Diabetes Res. Clin. Pract. 2020, 108137.
12. Guan W.-J., Ni Z.-Y., Hu Y., Liang W.-H., Ou C.-Q., He J.-X., Liu L., Shan H., Lei C.-L., Hui D.S. et al. Clinical Characteristics of Coronavirus Disease 2019 in China // N. Engl. J. Med. 2020, 382, 1708–1720
13. Gupta N., Zhao Y.Y., Evans C.E. The stimulation of thrombosis by hypoxia // Thromb Res. 2019. 181:77– 83. Epub 2019. 08. 04. https://doi.org/10.1016/j.thromres.2019.07.013 PMID: 31376606 (Дата обращения на сайт: 17.10.2022)
14. Helms J., Tacquard C., Severac F. et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study // Intensive Care Med 2020. 46: 1089–1098.
15. Ho Jamie S.Y. et al. Obesity in COVID-19: a systematic review and meta-analysis // Ann Acad Med Singap 49.12 (2020): 996-1008.
16. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan // China. Lancet 2020, 395, 497–506.
17. Jean-François Llitjos, Maxime Leclerc, Camille Chochois, Jean-Michel Monsallier, Michel Ramakers, Malika Auvray, Karim Merouani. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients // J. Thromb Haemost. 2020. V.18(7). Р.1743–1746
18. Kerbikov O., Orekhov P., Borskaya E., Nosenko N. High incidence of venous thrombosis in patients with moderate-to-severe COVID-19 // International journal of hematology, 2021. 113(3), 344–347. https://doi.org/10.1007/s12185-020-03061-y (Дата обращения на сайт: 17.11.2022)
19. Klok F.A., Kruip M.J., van der Meer N.J. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19 // Thromb Res. Epub ahead of print 2020. DOI: 10.1016/j.thromres.2020.04.013.
20. Klok F.A., Kruip M.J., van der Meer N.J., Arbous M.S., Gommers D.A., Kant K.M., Kaptein F.H., Paassen J. Stals M.A., Huisman M.V., Endemane H. Incidence of thrombotic complications in critically ill ICU patients with COVID-19 // Thromb Res. 2020. V.191. Р. 145–147.
21. Kucharski A.J., Russell T.W., Diamond C., Liu Y., Edmunds J., Funk S., Eggo R.M. Centre for Mathematical Modelling of Infectious Diseases COVID-19 working group Early dynamics of transmission and control of COVID-19: a mathematical modelling study. The Lancet. Infectious diseases, 2020. 20(5), 553–558. https://doi.org/10.1016/S1473-3099(20)30144-4 (Дата обращения на сайт: 10.11.2022)
22. Li B., Yang J., Zhao F., Zhi L., Wang X., Liu L., Bi Z., Zhao Y. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China // Clin. Res. Cardiol. 2020, 109, 531
23. Li J., Yan S., Zhang X. et al. Circulating D-Dimers Increase the Risk of Mortality and Venous Thromboembolism in Patients With Lung Cancer: A Systematic Analysis Combined With External Validation // Front Med (Lausanne). 2022. 9:853941. Published 2022 Mar 2. doi:10.3389/fmed.2022.853941
24. Lodigiani C., Iapichino G., Carenzo L. et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy // Thromb Res. 2020. 191: 9–14.
25. Ma R.C., Holt R.I. COVID-19 and diabetes // Diabet. Med. 2020, 37, 723–725.
26. Marone E.M., Rinaldi L.F. Upsurge of deep venous thrombosis in patients affected by COVID-19: preliminary data and possible explanations // J Vasc Surg Venous Lymphat Disord. 2020. 8: 694–695.
27. Middeldorp S., Coppens M., van Haaps T.F., et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19 // J Thromb Haemost. 2020. 18: 1995–2002.
28. Muniyappa R., Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. American journal of physiology. Endocrinology and metabolism, 2020. 318 (5), E736–E741. https://doi.org/10.1152/ajpendo.00124.2020 (Дата обращения на сайт: 21.10.2022)
29. Onder G., Rezza G., Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy // JAMA 2020, http://dx.doi.org/10.1001/jama.2020.4683 (Дата обращения на сайт: 19.09.2022)
30. Ren B., Yan F., Deng Z. et al. Extremely high incidence of lower extremity deep venous thrombosis in 48 patients with severe COVID-19 in Wuhan // Circulation 2020; 142: 181–183.
31. Rey Juan R et al. Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications // European journal of heart failure, 2020. vol. 22, 12: 2205-2215. doi:10.1002/ejhf.1990
32. Spiezia L., Boscolo. A., Poletto. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure // Thromb Haemost. 2020. V. 120(6). Р. 998–1000.
33. Suh Y.J., Hong H., Ohana M., Bompard F., Revel M. P., Valle C., Gervaise A. et al. Pulmonary Embolism and Deep Vein Thrombosis in COVID-19: A Systematic Review and Meta-Analysis // Radiology, 2021. 298(2), E70–E80. https://doi.org/10.1148/radiol.2020203557
34. Thomas W., Varley J., Johnston A. et al. Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom // Thromb Res. 2020. 191: 76–77
35. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China // JAMA 2020. 323:1061-9.
36. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y. et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia inWuhan, China // JAMA 2020, 323, 1061.
37. Wang T., Chen R., Liu C. et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19 // Lancet Haematol 2020. 7: e362–e363.
38. Wichmann D., Sperhake J.P., Lu¨tgehetmann M. et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study // Ann Intern Med 2020. 173: 268–277.
39. Wu J.T., Leung K., Bushman M., Kishore N., Niehus R., De Salazar P.M., Cowling B.J., Lipsitch M., Leung G.M. Estimating clinical severity of COVID-19 from the transmission dynamics inWuhan, China // Nat. Med. 2020, 26, 506–510.
40. Zhang L., Feng X., Zhang D., et al. Deep Vein Thrombosis in Hospitalized Patients With COVID-19 in Wuhan, China: Prevalence, Risk Factors, and Outcome // Circulation. 2020. 142: 114–128. Epub 2020 May 18. Erratum in: Circulation. 2020; 142: e33.
41. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song, B., Gu X. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study // Lancet 2020, 395, 1054–1062.
Number of Views: 71
Category of articles:
COVID-19 - Topical Subject
Bibliography link
Rakhimzhanova R.I., Kozhakhmetova Zh.J., Ozerman A. Assessment of risk factors for thrombosis in ICU patients with COVID-19 // Nauka i Zdravookhranenie [Science & Healthcare]. 2023, (Vol.25) 1, pp. 16-25. doi 10.34689/SH.2023.25.1.002Related publications:
IMMUNOLOGICAL CHANGES IN CHILDREN WITH MULTISYSTEM INFLAMMATORY SYNDROME ASSOCIATED WITH SARS-COV-2
EFFICACY OF THE ANTIVIRAL DRUG ENISAMY IODIDE IN SEVERE ADULT ACUTE RESPIRATORY INFECTIONS IN THE COVID-19 ERA
APPLICATION OF ARTIFICIAL INTELLIGENCE IN COMBATING THE COVID-19 PANDEMIC: CURRENT TRENDS AND PROSPECTS. REVIEW
CONSEQUENCES OF THE CORONAVIRUS INFECTION: THE POST-COVID SYNDROME AND MENTAL MANIFESTATIONS. LITERATURE REVIEW
FEATURES OF THE SICKNESS BEHAVIOR OF ARTERIAL HYPERTENSION AND OBESITY DURING THE PANDEMIC OF COVID-19 CORONAVIRUS. REVIEW